The purpose of the study is to find out whether the medication is safe and can be tolerated without serious side effects when used for an extended time. Participants will take the tablet daily and attend regular visits where simple checks are done, including blood or urine checks (lab test), a heart test that records electrical activity (ECG), and measurements of blood pressure and heart rate (vital signs) to see how the body is responding.

Throughout the study, any side effects, changes in the test results, and any serious health problems will be recorded and compared with the information collected at the start of the study. The trial is open‑label, meaning that both the researchers and participants know the medication being taken.

Participants in the study will be randomly assigned to receive either the GSK3915393 tablet or a placebo, which looks like the real medication but does not contain the active substance. The study will last for about 26 weeks, during which participants will take the medication regularly and attend scheduled visits to monitor their health and lung function. The main focus will be on measuring changes in lung capacity over time.

Throughout the study, participants will undergo various health checks, including assessments of vital signs like blood pressure and heart rate, as well as laboratory tests to ensure their safety. The trial aims to provide valuable information on whether GSK3915393 can help slow down the progression of Idiopathic Pulmonary Fibrosis and improve the quality of life for those affected by this condition.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

During the study, participants will receive either MTX-463 or placebo through intravenous administration over a period of 20 weeks. Some participants may continue their current IPF medications, such as pirfenidone or nintedanib, if they have been on a stable dose. The study will measure how well participants’ lungs work by checking their forced vital capacity (FVC), which is the amount of air a person can forcefully exhale after taking a deep breath.

The study will track any changes in participants’ lung function over 24 weeks. Throughout the study, doctors will monitor participants’ health through regular check-ups and tests. The research team will also keep track of any side effects that may occur during the treatment period. Some participants will receive sodium chloride solution or glucose solution as part of the study procedures.

The study uses two different treatments: some participants will receive BI 765423, while others will receive a placebo. Neither the patients nor their doctors will know which treatment is being given. The medication or placebo will be administered through an injection into a vein. The study will track changes in participants’ lung function over a period of 12 weeks.

During the study, various measurements will be taken to monitor lung function, including breathing tests and walking tests. Participants will be regularly monitored to ensure their safety throughout the treatment period. The study will last approximately 24 months, during which participants will need to attend multiple clinic visits for assessments and treatment administration.

Participants in this study will be assigned to receive different amounts of the medication, either AP02 High or AP02 Low, or a placebo. The study aims to determine how these doses affect lung function over a period of 12 weeks. During this time, the way the lungs work will be monitored to see if the treatment helps slow down the progression of the disease.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.

The purpose of the study is to evaluate the use of 68Ga-FAPI-46 to detect scar tissue inside the body. This substance is a radiopharmaceutical, which is a specialized drug used for medical imaging. Participants will undergo a PET/CT scan, a method that combines two types of imaging to create detailed pictures of the body’s internal structures. During the process, the substance is administered through an intravenous injection, meaning it is delivered directly into a vein.

Throughout the study, the imaging results will be compared with biological samples to see how well the scan identifies certain markers of scarring. Researchers will also look at how the substance moves through the body and how it can be used to better understand the progression of these diseases. This information may help in finding new ways to diagnose or treat scarring in the future.

During the study, researchers will monitor how the treatment affects the lungs, specifically looking at changes in Forced Vital Capacity, which is a measure of the total amount of air a person can exhale after taking a deep breath. The study also observes how the condition changes over time and examines the distance a person can walk during a 6-minute walk test, which is a common way to check physical fitness and lung function. The investigation will take place over a period of 52 weeks.

The purpose of this research is to determine if LTI-03 is safe and well-tolerated by patients who have been diagnosed with Idiopathic Pulmonary Fibrosis within the last 5 years. The medication will be tested in patients who may already be receiving standard treatment for their condition. The study will last for 24 weeks, during which participants will need to use an inhaler device to take their assigned medication.

Throughout the study, doctors will monitor patients’ lung function using various tests including forced vital capacity measurements and high-resolution computed tomography scans of the chest. They will also track any side effects that may occur during treatment. The study will evaluate how well participants can breathe and how their quality of life may change while using the study medication.

The purpose of the study is to evaluate how effective and safe CAL101 is for patients with IPF. Participants in the study will receive either CAL101 or a placebo, which is a substance with no active medication. The study will last for about 28 weeks, during which the lung function of participants will be closely monitored to see if there are any improvements. The main focus will be on changes in the amount of air the lungs can hold, known as forced vital capacity (FVC).

Throughout the study, participants will be observed for any side effects or adverse events. The study will also track how many participants experience these events over a period of 40 weeks. This research is important to understand if CAL101 can be a beneficial treatment option for those living with IPF.

Participants in this study will have previously taken part in other studies involving inhaled antifibrotic treatments. The study will observe participants over an extended period to monitor any side effects or changes in their condition. The goal is to gather information on how the treatment affects the progression of the lung diseases and to ensure it is safe for long-term use.

Throughout the study, researchers will keep track of any new health issues that arise, changes in lung function, and any serious health events. This information will help determine if the inhaled medication is a viable long-term treatment option for people with PPF and IPF. Participants will use the inhalation device as instructed and attend regular study visits to provide feedback and undergo health assessments.

The purpose of the study is to understand how well different doses of Taladegib work in patients with IPF over a period of 24 weeks. Participants in the study will be randomly assigned to receive either Taladegib or a placebo, which looks like the Taladegib tablet but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication orally and will be monitored for changes in their lung function and symptoms. The study will last for about six months, during which time the researchers will collect data on how the treatment affects the progression of the disease, including any changes in breathing ability and overall health. The goal is to determine if Taladegib can help slow down or improve the symptoms of IPF compared to the placebo.

Participants in the study will be randomly assigned to receive either the BI 1839100 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for 12 weeks, during which the participants will take the medication orally. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

The main goal is to observe any changes in the frequency of coughing over the course of the study. Researchers will also look at how different doses of BI 1839100 affect cough frequency and assess the safety of the medication. This study aims to provide valuable information on whether BI 1839100 can be an effective treatment for reducing cough in patients with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis.

The purpose of the study is to determine if inhaled Treprostinil can improve lung function over a period of 52 weeks. Participants will use a device called a nebuliser to inhale the medication. This device turns the liquid medication into a mist that can be easily inhaled into the lungs. The study will monitor changes in lung function and other health outcomes over the course of the year.

Throughout the study, participants will have regular check-ups to assess their lung function and overall health. The main goal is to see if there is an improvement in lung capacity, which is measured by a test called Forced Vital Capacity (FVC). The study will also look at other factors such as the time it takes for the disease to worsen, any hospitalizations due to breathing problems, and overall survival rates. This research is important for understanding how Treprostinil might help people with IPF manage their symptoms and improve their quality of life.

Participants in the study will be randomly assigned to receive either BI 1819479 or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for at least 24 weeks, and participants will take the medication orally. The researchers aim to find the most effective dose of BI 1819479 by comparing different doses to the placebo.

Throughout the study, the main focus will be on measuring changes in lung function, specifically the rate at which lung capacity declines over time. This will help determine if BI 1819479 can slow down the progression of IPF. The study will also look at the safety and tolerability of the medication to ensure it is safe for patients to use.

The purpose of this research is to determine if Tezepelumab can reduce the number of eosinophils in the blood compared to placebo after 24 weeks of treatment in people with progressive pulmonary fibrosis. The medication will be administered through subcutaneous injection at a dose of 210 mg.

During the study, participants will receive either Tezepelumab or placebo for 24 weeks. After this initial period, some participants may continue receiving treatment in what is called an open-label extension phase. Throughout the study, doctors will monitor various aspects of lung function and overall health through different tests and examinations to evaluate how well the treatment works.

Participants in the study will receive either the glucocorticoid treatment or a placebo. The study will monitor the participants’ health over a period of time, focusing on their survival rate at 30 days. Other aspects of their health will also be observed, such as their lung function, any need for intensive care, and overall well-being. The study aims to gather information on how effective glucocorticoids are in managing the acute worsening of IPF and whether they can improve the outcomes for patients.

Throughout the study, various health parameters will be checked, including blood sugar levels, heart rate, and blood pressure. The study will also look at any changes in the participants’ lung condition and their overall health status. This research hopes to provide valuable insights into the treatment of IPF and potentially improve the quality of life for those affected by this challenging condition.

Participants in the study will be randomly assigned to receive either Buloxibutid or a placebo. The study will last for 52 weeks, during which participants will take the medication regularly. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The main focus will be on changes in lung function, specifically measuring how much air participants can exhale after taking a deep breath, known as Forced Vital Capacity (FVC).

The trial aims to gather information on how Buloxibutid affects the progression of IPF, including any changes in symptoms like cough and shortness of breath. It will also look at the overall health and quality of life of participants. By the end of the study, researchers hope to determine if Buloxibutid can help improve lung function and slow down the progression of IPF.

Participants in the study will be randomly assigned to receive either the LTP001 treatment or a placebo. The study will last for about 26 weeks, during which participants will take the assigned capsules regularly. Throughout the study, participants will have their lung function monitored to see if there are any changes in their breathing capacity. This will help researchers understand how well the treatment works and if there are any side effects.

The study aims to provide valuable information on the potential benefits of LTP001 for people living with Idiopathic Pulmonary Fibrosis. By comparing the effects of the treatment to a placebo, researchers hope to determine if LTP001 can improve lung function and overall health in patients with this challenging condition.

The purpose of the study is to understand how Bexotegrast affects lung function in people with IPF over a period of 52 weeks. Participants will be randomly assigned to receive either Bexotegrast or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The main focus will be on changes in lung capacity, specifically measuring something called forced vital capacity (FVC), which is a way to assess how well the lungs are working.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The study will also look at other aspects of the disease, such as the time it takes for the disease to progress, changes in symptoms like cough and breathlessness, and overall quality of life. The safety of Bexotegrast will be closely monitored by tracking any side effects or serious health events that occur during the study period.

The purpose of the study is to evaluate how Axatilimab affects lung function in people with IPF. Participants will be randomly assigned to receive either Axatilimab or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for 26 weeks, during which participants will have regular check-ups to monitor their lung function and overall health.

Throughout the study, researchers will measure the rate of decline in lung capacity, which is how much air the lungs can hold, and observe any changes in symptoms or disease progression. The study aims to provide valuable information on the safety and effectiveness of Axatilimab as a potential treatment for IPF, helping to improve the quality of life for those affected by this condition.

The purpose of the study is to evaluate how these treatments affect the decline in lung function over a period of 24 weeks. Participants will take the medications in the form of capsules or tablets, and their lung function will be measured at the start of the study and then again at weeks 4, 12, and 24. This will help determine how well the treatments are working in slowing down the progression of the disease.

Throughout the study, the tolerance of the medications will also be monitored, which means checking how well participants can handle the treatment without significant side effects. The study will also look at other factors, such as the time it takes for participants to stop the medication permanently, any hospitalizations related to lung issues, and overall survival without hospital admissions. The goal is to find the most effective way to manage IPF and improve the quality of life for those affected by this condition.

The purpose of this study is to understand how well BI 1015550 works over a long period and to check its safety in patients who have already participated in previous studies with this medication. Participants will continue taking the medication as they did in the earlier trials, and the study will monitor them for any side effects or changes in their condition. The study will last for about 99 weeks, during which time participants will have regular check-ups to assess their health and the medication’s effects.

This trial does not involve comparing BI 1015550 with other treatments or a placebo. Instead, it focuses on observing the experiences of those taking the medication. The study aims to gather information on any adverse events and changes in lung function over time, helping to determine the long-term benefits and risks of using BI 1015550 for treating IPF and PPF.

The purpose of the study is to gather information about the safety, how well patients tolerate the treatment, and how effective it is in treating IPF. Participants in the study will be randomly assigned to one of four groups. Some will receive Deupirfenidone, others will receive Pirfenidone, and some will receive a placebo. The study will last for about 26 weeks, during which time participants will take the medication in the form of tablets or capsules. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The main focus will be on measuring changes in lung function and overall health. The study aims to find the best dose of Deupirfenidone that provides the most benefit with the fewest side effects. This research is important for developing better treatments for people living with IPF.

The goal of the study is to test the impact of two different doses of HZN-825 compared to a placebo, over a 52-week period. Participants will take the medication in tablet form by mouth. The primary focus is to see if there are changes in lung function, specifically in a measure called forced vital capacity (FVC), which relates to how much air a person can forcefully exhale from their lungs after taking a deep breath. This measure is crucial as it can indicate the progression of lung conditions like IPF.

In addition to evaluating the lung capacity, other aspects such as safety and side effects of the treatment will be observed. The trial is structured in two parts; the initial phase involves a comparison with a placebo, and the subsequent extension phase continues to assess the medication’s effectiveness over a longer period with open-label treatment, meaning that participants will know they are receiving the actual drug.

The purpose of the study is to evaluate how effective inhaling Alveofact® is in improving lung function in patients with IPF. The study will compare the effects of the treatment to a placebo, which is a substance with no active medication. Participants will receive the treatment over a period of time, and their lung function will be measured to see if there are any improvements. The main focus will be on changes in the Forced Vital Capacity (FVC), which is a measure of how much air a person can exhale after taking a deep breath.

Throughout the study, participants will undergo various assessments to monitor their lung health and overall well-being. These assessments will include measuring lung capacity, oxygen levels, and the distance they can walk in six minutes. The study aims to provide valuable information on whether inhaling Alveofact® can help improve breathing and quality of life for people with IPF. Participants will be closely monitored for any side effects or changes in their condition during the study period.

Participants in the study will take MBS2320 or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for 12 weeks, during which participants will take the medication daily. Researchers will monitor changes in lung function, specifically looking at something called forced vital capacity (FVC), which measures how much air a person can exhale after taking a deep breath. This will help determine if MBS2320 can improve breathing in people with IPF.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study aims to provide valuable information on whether MBS2320 can be a beneficial treatment option for those living with IPF. Participants’ progress will be closely monitored to ensure their safety and to gather data on the treatment’s effects.

The purpose of the study is to evaluate how well Nalbuphine ER can reduce the number of coughs a person with IPF experiences over a 24-hour period. Participants in the study will be randomly assigned to one of four groups, each receiving different doses of Nalbuphine ER or a placebo. The study will last for six weeks, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, participants will be monitored to assess changes in their cough frequency and any potential side effects.

By the end of the study, researchers aim to determine the most effective dose of Nalbuphine ER for reducing cough in people with IPF. The study will also gather information on any side effects experienced by participants to ensure the treatment is safe. This research could lead to improved management of cough symptoms in individuals living with IPF, potentially enhancing their quality of life.

The purpose of the study is to evaluate how well Vixarelimab works in improving lung function. Participants will receive either Vixarelimab or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for a period of up to 104 weeks, during which various health assessments will be conducted to monitor changes in lung function and overall health.

Throughout the study, participants will undergo regular check-ups to measure changes in their lung capacity and other health indicators. The study aims to provide valuable information on the safety and effectiveness of Vixarelimab in treating these lung diseases, potentially leading to better treatment options in the future.